-transparent.png){kind=logo}
Twenty-seven hypertensive patients (23 blacks, 4 whites) treated with hydralazine had frequent serologic evidence of autoimmunity. However, only 1 patient developed a lupus syndrome. Acetylator phenotype influenced the autoimmune response; slow acetylators had a higher incidence and titers of autoantibodies. The lupus patient not only had high titers of autoantibodies but they were predominantly IgG in contrast to the predominant IgM antibodies found in other slow acetylators. Hydralazine treatment did not alter cell-mediated immune responses and hydralazine antibodies were not detected. However, half the patients tested who received hydralazine had positive lymphoproliferative responses to the drug.
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
October 1968,
The Medical annals of the District of Columbia,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
February 1955,
Circulation,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
December 1980,
Clinical pharmacology and therapeutics,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
June 1970,
American heart journal,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
August 1981,
Arthritis and rheumatism,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
March 1990,
The American journal of the medical sciences,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
January 1982,
European journal of clinical pharmacology,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
September 1954,
Geriatrics,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
January 1975,
Arthritis and rheumatism,
A Litwin, and
L E Adams, and
H Zimmer, and
E V Hess
October 1960,
Canadian Medical Association journal,
